Head-to-head evidence
Aclidinium bromide vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Covis Pharma
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo and used trough FEV1, an accepted clinical lung-function endpoint for COPD, as its primary outcome at 12 and 28 weeks. Aclidinium showed higher reported mean FEV1 values at both time points, but because statistical significance for the primary comparisons is not reported, the result is considered unclear rather than definitively met.
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Next expected readout: December 2026 · NCT07133880 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Umeclidinium's landscape